What is HC Wainwright's Estimate for DNLI FY2025 Earnings?

Key Points

• HC Wainwright has revised its **FY2025 earnings per share (EPS)** estimate for Denali Therapeutics to **($2.91)**, down from a previous estimate of **($2.87)**, while maintaining a **Buy rating** and a **$32.00 price target**.
• The company reported a quarterly earnings result of **($0.72) EPS**, which beat the consensus estimate of **($0.74)**.
• Recent insider trading activity showed CEO Ryan J. Watts sold **495,282 shares**, indicating a **66.18% decrease** in his ownership stake in Denali Therapeutics.

Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) - Analysts at HC Wainwright cut their FY2025 earnings per share estimates for shares of Denali Therapeutics in a note issued to investors on Tuesday, August 12th. HC Wainwright analyst A. Fein now anticipates that the company will post earnings per share of ($2.91) for the year, down from their prior estimate of ($2.87). HC Wainwright currently has a "Buy" rating and a $32.00 price objective on the stock. The consensus estimate for Denali Therapeutics' current full-year earnings is ($2.71) per share. HC Wainwright also issued estimates for Denali Therapeutics' FY2026 earnings at ($2.43) EPS and FY2027 earnings at ($1.09) EPS.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last released its quarterly earnings data on Monday, August 11th. The company reported ($0.72) earnings per share for the quarter, beating analysts' consensus estimates of ($0.74) by $0.02. During the same period in the previous year, the business posted ($0.59) EPS.

Several other equities analysts have also weighed in on the company. Bank of America cut their price target on Denali Therapeutics from $28.00 to $27.00 and set a "buy" rating for the company in a research note on Monday, May 19th. Robert W. Baird cut their price target on Denali Therapeutics from $30.00 to $29.00 and set an "outperform" rating for the company in a research note on Thursday, May 8th. TD Cowen upgraded Denali Therapeutics to a "strong-buy" rating in a research note on Monday, July 28th. William Blair upgraded Denali Therapeutics to a "strong-buy" rating in a research note on Thursday, April 24th. Finally, Wedbush cut their price target on Denali Therapeutics from $32.00 to $30.00 and set an "outperform" rating for the company in a research note on Wednesday, May 7th. Three investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has issued a Hold rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Buy" and a consensus target price of $33.62.

Denali Therapeutics Stock Performance

Shares of NASDAQ DNLI traded down $0.30 during trading on Friday, reaching $14.51. 1,425,445 shares of the company traded hands, compared to its average volume of 1,407,680. The firm's fifty day simple moving average is $14.29 and its 200 day simple moving average is $15.19. The stock has a market cap of $2.12 billion, a P/E ratio of -5.18 and a beta of 1.36. Denali Therapeutics has a 12-month low of $10.57 and a 12-month high of $33.33. The company has a current ratio of 10.27, a quick ratio of 10.27 and a debt-to-equity ratio of 0.01.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Wellington Management Group LLP lifted its holdings in Denali Therapeutics by 15.9% in the first quarter. Wellington Management Group LLP now owns 11,409,598 shares of the company's stock valued at $155,113,000 after acquiring an additional 1,561,647 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in Denali Therapeutics by 88.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 6,766,916 shares of the company's stock valued at $91,996,000 after acquiring an additional 3,184,042 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in Denali Therapeutics by 42.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 4,367,234 shares of the company's stock valued at $59,373,000 after acquiring an additional 1,308,619 shares during the last quarter. Norges Bank acquired a new position in Denali Therapeutics in the second quarter valued at approximately $55,224,000. Finally, Geode Capital Management LLC lifted its holdings in Denali Therapeutics by 4.4% in the second quarter. Geode Capital Management LLC now owns 3,172,305 shares of the company's stock valued at $44,386,000 after acquiring an additional 135,129 shares during the last quarter. 92.92% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Denali Therapeutics

In other news, CEO Ryan J. Watts sold 495,282 shares of the business's stock in a transaction that occurred on Wednesday, July 9th. The stock was sold at an average price of $15.00, for a total transaction of $7,429,230.00. Following the transaction, the chief executive officer directly owned 253,071 shares in the company, valued at $3,796,065. The trade was a 66.18% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Alexander O. Schuth sold 2,937 shares of the business's stock in a transaction that occurred on Tuesday, August 12th. The stock was sold at an average price of $13.58, for a total value of $39,884.46. Following the transaction, the insider owned 242,346 shares in the company, valued at approximately $3,291,058.68. This represents a 1.20% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 501,962 shares of company stock worth $7,520,799 in the last ninety days. Insiders own 12.50% of the company's stock.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.